Krystal Biotech, Inc. Common Stock

Krystal Biotech's 38.2x P/E ratio stands dramatically elevated against its sector peers, reflecting outsized growth expectations baked into a $7.8B valuation. The stock trades well below its 52-week high with a neutral RSI of 50.6, suggesting neither momentum-driven extremes nor capitulation. For a biotech firm in the basic materials/biological products space, this valuation demands execution—clinical wins, regulatory approvals, or revenue inflection are priced in. The modest distance from highs coupled with this stretched multiple creates meaningful downside risk if pipeline progress stalls, while the absence of extreme technical overbought conditions indicates room for further upside on positive catalysts. Current positioning appears more speculative than momentum-driven.